Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial …
EF Morand, T Trasieva, A Berglind, GG Illei… - Annals of the …, 2018 - ard.bmj.com
Objectives In a post-hoc analysis, we aimed to validate the Lupus Low Disease Activity State
(LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb …
(LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb …
Systemic lupus erythematosus: all roads lead to type I interferons
V Pascual, L Farkas, J Banchereau - Current opinion in immunology, 2006 - Elsevier
In recent years, the study of systemic lupus erythematosus (SLE) patients has revealed a
central role for type I interferon (IFN) in disease pathogenesis. IFN induces the unabated …
central role for type I interferon (IFN) in disease pathogenesis. IFN induces the unabated …
Targeting interferons and their pathways in systemic lupus erythematosus
F Chasset, L Arnaud - Autoimmunity reviews, 2018 - Elsevier
Significant advances in the understanding of the molecular basis of innate immunity have
led to the identification of interferons (IFNs), particularly IFN-α, as central mediators in the …
led to the identification of interferons (IFNs), particularly IFN-α, as central mediators in the …
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
JM Riggs, RN Hanna, B Rajan, K Zerrouki… - Lupus science & …, 2018 - lupus.bmj.com
Objective We investigated the mechanistic and pharmacological properties of anifrolumab, a
fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal …
fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal …
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2 …
Background Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's …
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's …
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
DJ Wallace, V Strand, JT Merrill, S Popa… - Annals of the …, 2017 - ard.bmj.com
Objectives This phase II trial evaluated the efficacy and safety of an interleukin (IL) 6
monoclonal antibody for systemic lupus erythematosus (SLE). Methods Patients with active …
monoclonal antibody for systemic lupus erythematosus (SLE). Methods Patients with active …
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
M Northcott, S Jones, R Koelmeyer, J Bonin… - Lupus science & …, 2022 - lupus.bmj.com
Objectives Type 1 interferon (IFN) is key to the pathogenesis of SLE, evidenced by the
expression of IFN-stimulated genes (ISGs) in most patients, but the clinical utility of serial …
expression of IFN-stimulated genes (ISGs) in most patients, but the clinical utility of serial …
Sifalimumab, a human anti–interferon‐α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose‐escalation study
M Petri, DJ Wallace, A Spindler… - Arthritis & …, 2013 - Wiley Online Library
Objective To evaluate the safety and tolerability of multiple intravenous (IV) doses of
sifalimumab in adults with moderate‐to‐severe systemic lupus erythematosus (SLE) …
sifalimumab in adults with moderate‐to‐severe systemic lupus erythematosus (SLE) …
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial
JY Humrich, P Cacoub, M Rosenzwajg… - Annals of the …, 2022 - ard.bmj.com
Objectives A regulatory T cell (Treg) insufficiency due to shortage of interleukin-2 (IL-2) is
central to the pathophysiology of systemic lupus erythematosus (SLE). We performed a …
central to the pathophysiology of systemic lupus erythematosus (SLE). We performed a …
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
SLE is an autoimmune condition characterized by loss of tolerance to chromatin constituents
and the production of ANAs. The majority of SLE patients display spontaneous expression of …
and the production of ANAs. The majority of SLE patients display spontaneous expression of …